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Abstract
Background:  The ability of Plasmodium falciparum-infected erythrocytes to adhere to the
microvasculature endothelium is thought to play a causal role in malaria pathogenesis. Cytoadhesion to
endothelial receptors is generally found to be highly sensitive to trypsinization of the infected erythrocyte
surface. However, several studies have found that parasite adhesion to placental receptors can be
markedly less sensitive to trypsin. This study investigates whether chondroitin sulphate A (CSA) binding
parasites express trypsin-resistant variant surface antigens (VSA) that bind female-specific antibodies
induced as a result of pregnancy associated malaria (PAM).
Methods: Fluorescence activated cell sorting (FACS) was used to measure the levels of adult Scottish and
Ghanaian male, and Ghanaian pregnant female plasma immunoglobulin G (IgG) that bind to the surface of
infected erythrocytes. P. falciparum clone FCR3 cultures were used to assay surface IgG binding before and
after selection of the parasite for adhesion to CSA. The effect of proteolytic digestion of parasite
erythrocyte surface antigens on surface IgG binding and adhesion to CSA and hyaluronic acid (HA) was
also studied.
Results: P. falciparum infected erythrocytes selected for adhesion to CSA were found to express trypsin-
resistant VSA that are the target of naturally acquired antibodies from pregnant women living in a malaria
endemic region of Ghana. However in vitro adhesion to CSA and HA was relatively trypsin sensitive. An
improved labelling technique for the detection of VSA expressed by CSA binding isolates has also been
described.
Conclusion: The VSA expressed by CSA binding P. falciparum isolates are currently considered potential
targets for a vaccine against PAM. This study identifies discordance between the trypsin sensitivity of CSA
binding and surface recognition of CSA selected parasites by serum IgG from malaria exposed pregnant
women. Thus, the complete molecular definition of an antigenic P. falciparum erythrocyte surface protein
that can be used as a malaria in pregnancy vaccine has not yet been achieved.
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Background
Rapid clearance of parasitaemia following transfusion of
IgG from malaria immune adults to clinically ill recipients
illustrates that naturally acquired antibodies have a para-
site clearing role in human malaria infection [1-3]. Nei-
ther the nature of the protective immune response nor the
target antigens and epitopes recognized by infection clear-
ing antibodies are fully understood. Evidence is accumu-
lating to suggest that the acquisition of antibodies binding
the VSA on infected erythrocytes plays a major role in the
development of age and exposure dependent immunity
[4-8]. The evidence for protective anti-VSA responses is
particularly strong for the PAM syndrome [9,10].
PAM is characterized by the sequestration of Plasmodium
falciparum infected erythrocytes in the intervillous spaces
of the placenta. Infected erythrocytes adhere to low-sul-
phated forms of CSA present on the extracellular prote-
oglycan matrix of syncytiotrophoblasts [11]. In vitro
selection of infected erythrocytes for adhesion to CSA con-
comitantly selects for expression of VSA that share charac-
teristics with postnatal placental isolates. Thus plasma
antibodies from malaria exposed pregnant, or multi-
gravid women, recognize the VSA of CSA binding para-
sites (here referred to as VSAPAM). These sera can also
block adhesion of CSA-selected infected erythrocytes to
CSA in vitro [12]. Interestingly, antibodies that bind CSA-
selected parasites and block adhesion are not acquired by
malaria-exposed males. There is a striking female-specific
antibody response recognizing both in vitro CSA-selected
parasites [12,13] and P. falciparum isolates taken from
infected placentae at delivery [14-16]. Furthermore, the
levels of CSA-adhesion blocking plasma IgG have been
shown to increase with adult female parity. Recent
immuno-epidemiological studies also show a strong pos-
itive correlation between the levels of antibodies that rec-
ognize the infected erythrocyte surface[15], the level of
CSA-adhesion blocking antibody [17] and positive birth
outcomes as measured by birth weight.
PAM is, thus, the clearest example in malaria pathology
research of a strong association between infected erythro-
cyte sequestration and a particular disease syndrome. The
VSA recognized by female-specific, parity-dependent anti-
bodies are, therefore, rational and exceptionally interest-
ing candidates for inclusion in an experimental vaccine to
protect women against PAM, a major cause of stillbirth,
maternal anaemia and low birthweight.
To date, the best characterized VSA is P. falciparum eryth-
rocyte membrane protein 1 (PfEMPl), a polymorphic,
high molecular weight membrane protein (200–450 kDa)
encoded by the var multi-gene family [18-20]. Members
of the PfEMP-1 family function as adhesion molecules
binding to various host endothelial receptors. They are sit-
uated in the knob-like protrusions associated with the
parasitized erythrocyte surface.
Since var genes encode large extracellular domains rich in
lysine and arginine residues, it is not surprising that
PfEMP-1 molecules and adhesion to endothelial receptors
have been reported to be highly sensitive to trypsin treat-
ment [18,21-24]. Less expected was the finding that para-
site adhesion to the placental receptor CSA, when
immobilized [25-27] or when cell surface associated
[28,29], can be relatively trypsin resistant. This study
investigates the protease-sensitivity profile of the VSAPAM
expressed by CSA-selected parasite clone FCR3 with
regard to recognition by antibodies acquired during PAM
and adhesion to placental receptors.
Methods
Parasite isolates
Parasites were maintained in group O erythrocytes under
standard conditions [30], using RPMI 1640 medium con-
taining 25 mM HEPES, supplemented with 20 mM glu-
cose, 2 mM glutamine, 25 µg/ml gentamycin and 10%
pooled normal human serum. The pH was adjusted to
between 7.2 and 7.4 with 1 M NaOH. Culture flasks at 5%
haematocrit were gassed with 96% nitrogen, 3% carbon
dioxide and 1% oxygen. The laboratory clone FCR3 origi-
nates from peripheral blood collected in the Gambia.
FCR3CSA was obtained from the Malaria Research and
Reference Reagent Resource Centre (ATCC) [31], and was
confirmed, using genetic markers to be identical to the
laboratory clone FCR3 kept in the original W.H.O. strain
registry collection in Edinburgh (D. Walliker, pers.
comm.). CSA binding was maintained by panning late
stage infected erythrocytes fortnightly on bovine tracheal
CSA (10 µg/ml) (Sigma) immobilized on polystyrene
Petri dishes (Falcon), as previously described [26]. Prior
to protease treatment and analysis by flow cytometry, cul-
tures were synchronized by sorbitol treatment to obtain
cultures enriched for late stage parasites.
Plasma donors
Serum samples from 20 men living in a malaria endemic
region of Ghana were pooled to produce the male serum
pool. Serum samples collected at the time of birth from
the placentas of 15 women living in a malaria endemic
region of Ghana were pooled to produce the pregnant
female serum pool. This pool included five primigravidae,
nine secundigravidae and one multigravid woman. Serum
samples from six Scottish malaria naïve individuals were
pooled and used as a control.
Protease treatment
Protease treatment of infected erythrocytes was carried out
as previously described [26]. Briefly, samples containing 3
× 106 cells from sorbitol treated late stage cultures of 8–10Malaria Journal 2004, 3:31 http://www.malariajournal.com/content/3/1/31
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% parasitaemia were washed twice with phosphate-buff-
ered saline (PBS) and then incubated with the appropriate
concentration of trypsin-TPCK (Worthington Biochemi-
cals) or pronase (Boehringer-Mannheim) in a final vol-
ume of 1.0 ml in PBS, for 10 minutes at 37°C. The
reaction was terminated either by adding soybean trypsin
inhibitor (Worthington Biochemicals) to a final concen-
tration of 1 mg/ml or by adding 10% human serum. Cells
were washed twice with PBS before further use.
Analysis of VSA specific antibodies by flow cytometry
Flow cytometry was used to measure the levels of plasma
IgG binding to the VSA of late stage parasites essentially
following the method previously described by Staalsoe et
al [13,32]. 3 × 106 cells form late stage P. falciparum cul-
tures of 8–10 % parasitaemia were washed twice with PBS.
Cells were incubated sequentially with plasma antibodies
diluted 1:20 in PBS, goat anti-human IgG diluted 1:200 in
PBS (Dako) and fluorescein isothiocyante (FITC)-conju-
gated rabbit anti-goat (Dako) diluted 1:25 in PBS. All
incubations were in a total volume of 100 µl for 30 min-
utes at room temperature and were followed by two
washes with 1 ml of PBS. Samples were analysed immedi-
ately on a FACSCAN apparatus (Becton-Dickinson). FITC
fluorescence due to cell surface antibody recognition was
determined for 5000–10000 ethidium bromide gated
infected erythrocytes.
Modified labeling procedure for FACS analysis
In order to circumvent the non-specific labeling of the
VSA by the tertiary antibody, new reagents have been
introduced. The procedure follows the method detailed
above with the following modifications. A biotinylated
rabbit anti-human IgG antibody (DAKO) was used
diluted 1:25 to replace the secondary antibody. In the
place of a tertiary antibody, FITC-conjugated streptavidin
(DAKO) was used at a 1:2000 dilution. In these experi-
ments the control sera was a pool of malaria naïve Danish
volunteer serum.
Binding assays
Human umbilical cord hyaluronic acid (Sigma) and
bovine trachea CSA (Sigma) were used at a concentration
of 10 µg/ml in PBS (pH 7.2). 20 µl of each receptor was
spotted in triplicate onto 5 cm diameter petri dishes (Fal-
con). Receptors were adsorbed onto the plastic petri
dishes overnight at 4°C. 10 µg/ml BSA in PBS was simi-
larly adsorbed as a negative control. Plates were then
blocked by removing the receptor solution and adding 20
µl of 2% BSA in PBS. Following the removal of this block-
ing solution late stage parasites, suspended in 2 ml of
complete RPMI-HEPES medium (8–10% parasitaemia,
5% haematocrit), were added to the petri dish. Parasites
were incubated with the immobilized receptor for 60
minutes at 37°C with occasional agitation. Unbound cells
were removed by four gentle washes with incomplete
RPMI-HEPES medium; bound cells were fixed with 0.5%
(v/v) glutaraldehyde in PBS for 10 minutes and Giesma
Stained. Bound cells were counted by light microscopy.
Protease treatment of intact cells was carried out as
described above.
Statistical analysis
Statistical analyses were performed using Analyses of Var-
iance in Minitab 13.30 (Minitab Inc.), using protease,
protease concentration and serum pool as explanatory
variables. Statistical models were tested for homogeneity
of variance and normality of error distributions. Where
possible, maximal models with interactions between
these variables were fitted first, after which models were
minimized by removing nonsignificant (p > 0.05) terms.
Results
Concomitant selection of a trypsin-resistant VSA following 
parasite selection for CSA adhesion
It was first established that selection of clone FCR3 for
adhesion to CSA resulted in the concomitant selection for
VSA specifically recognized by plasma IgG from malaria
exposed Ghanaian pregnant women (IgGpreg) (figure 1).
However there was no increase in the binding of IgG from
a pool of plasma from malaria exposed Ghanaian men
(IgGmale). The unselected FCR3 clone expressed VSA that
were equally well recognized by antibodies in the IgGmale
and IgGpreg  serum pools (figure 1). These interactions
between serum antibody binding and selection for CSA
adhesion were highly significant (F2,24 9.5, P = 0.001).
The trypsin sensitivity of this VSA/IgG binding interaction
and of parasite adhesion to CSA was then measured. Par-
asitized erythrocyte surface trypsinization at a concentra-
tion of 0.1 mg/ml showed that the IgGpreg binding of
FCR3CSA was significantly more trypsin-resistant than
was binding of the same serum to the unselected clone
(figure 2A &2B; F1,416.4, p = 0.015). Although the mean
surface fluorescence due to the IgGpreg  binding of
FCR3CSA was slightly reduced by 0.1 mg/ml trypsin this
reduction was not significant (figure 2A; F1,2 11.3, p =
0.078). The effect of 0.1 mg/ml trypsin on VSA recogni-
tion by IgGmale and IgGcontrol was comparable before
and after CSA selection of the parasite (figure 2).
The effect of a 10-fold higher trypsin concentration and
the effect of the non-specific protease, pronase, on IgG
recognition of FCR3CSA was also determined. Trypsiniza-
tion with 1 mg/ml did not significantly reduce the mean
surface fluorescence due to IgGpreg binding to FCR3CSA
(figure 3; F1,4 0.35, p = 0.587). However, treatment of the
intact infected erythrocyte with 0.1 mg/ml pronase did
significantly reduce IgGpreg  recognition of FCR3CSA
(figure 3). Pronase treatment also significantly reducedMalaria Journal 2004, 3:31 http://www.malariajournal.com/content/3/1/31
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binding of the IgGmale and IgGcontrol serum pools (figure
3; F4,183.1, p = 0.041).
Surprisingly, IgGcontrol binding to the infected erythro-
cyte surface increased following CSA selection of the par-
asite (figure 1); however, this non-immune recognition
was found to be significantly more trypsin sensitive than
IgGpreg recognition (figure 3; F4,183.11, p = 0.041). This
indicates that the epitopes recognized by the IgGcontrol
serum pool and the epitopes recognized by the IgGpreg
serum pool are distinct entities. An increase in apparent
non-immune immunoglobulin binding to the infected
erythrocyte surface has been observed for a number of
parasite clones after selection for adhesion to CSA (data
not shown). The source of this background labelling of
FCR3CSA by naïve sera was found to be due to non-spe-
cific binding by the FITC-labelled tertiary rabbit anti-goat
antibody. By using the modified antibody labelling proce-
dure, which employs a biotin-labelled secondary anti-
body and FITC-labelled streptavidin, binding of malaria
IgG recognition profiles of parasite clone FCR3 before and  after selection for adhesion to CSA Figure 1
IgG recognition profiles of parasite clone FCR3 
before and after selection for adhesion to CSA. Fol-
lowing selection of parasite clone FCR3 for adhesion to CSA 
the expression of variant surface antigens was investigated 
using FACS. 5000–10000 late stage parasites were gated 
using ethidium bromide and FITC fluorescence due to serum 
IgG binding was measured. Serum samples from six Scottish 
malaria naïve individuals were pooled and used as a control 
(IgGcontrol). Sera from 20 Ghanaian men were pooled to 
produce the malaria exposed male serum pool (IgGmale). 
Sera collected at the time of birth from the placentas of 15 
Ghanaian women were pooled to produce the malaria 
exposed pregnant female serum pool (IgGpreg). The bar 
chart shows mean and standard error of the means for five 
independent experiments.
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Serum IgG from malaria exposed pregnant women recog- nises trypsin-resistant surface epitopes Figure 2
Serum IgG from malaria exposed pregnant women 
recognises trypsin-resistant surface epitopes. Intact 
infected erythrocytes were treated with 0.1 mg/ml trypsin 
prior to FACS analysis. Panels A and B show serum IgG bind-
ing to the surface of FCR3CSA and FCR3 infected erythro-
cytes respectively. Serum pools are the same as those 
described in Figure 1. The bar chart shows mean and stand-
ard error of the means for two independent experiments.Malaria Journal 2004, 3:31 http://www.malariajournal.com/content/3/1/31
Page 5 of 8
(page number not for citation purposes)
naive IgG to FCR3CSA (mean fluorescence index = 16)
was comparable to the unselected parasite (mean fluores-
cence index = 17). Thus the recognition of VSAPAM by
malaria naive IgG was abolished (figure 4).
Discordance between the protease sensitivity of the CSA 
adhesion interaction and IgG binding
Following the identification of trypsin-resistant epitopes
that appear to be concomitantly selected with CSA adhe-
sion, the trypsin sensitivity of CSA adhesion itself was
determined. FCR3CSA binding to immobilised CSA was
markedly more sensitive to trypsin than IgGpreg recogni-
tion of the infected erythrocyte surface (figure 5). Parasite
adhesion was reduced by 81% and 91% following
treatment with 0.1 mg/ml trypsin and 1 mg/ml trypsin
respectively (figure 5). A trypsin concentration of 1 mg/ml
reduced binding as efficiently as 0.1 mg/ml pronase, and
although 0.1 mg/ml pronase significantly reduced cell
surface fluorescence due to IgGpreg antibody binding, 1
mg/ml trypsin had no significant effect on IgGpreg anti-
body binding. There is, thus, significant discordance
between the high trypsin sensitivity of CSA adhesion and
the relatively trypsin-insensitive binding of IgGpreg serum
antibodies to the infected erythrocyte surface (F1,8 14.4, p
= 0.005).
FCR3CSA expresses surface antigens exhibiting differential  protease sensitivity Figure 3
FCR3CSA expresses surface antigens exhibiting dif-
ferential protease sensitivity. Intact infected erythro-
cytes were treated with 1.0 mg/ml trypsin or 0.1 mg/ml 
pronase prior to FACS analysis. Serum pools are the same as 
those described in Figure 1. The bar chart shows mean and 
standard error of the means for three independent 
experiments.
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A modified antibody labelling procedure for FACS analysis of  CSA selected parasites Figure 4
A modified antibody labelling procedure for FACS 
analysis of CSA selected parasites. In order to circum-
vent the non-specific labelling of FCR3CSA VSA seen when 
using the FITC rabbit anti-goat tertiary antibody, a bioti-
nylated rabbit anti-human antibody in combination with 
FITC-conjugated streptavidin was used. Panels A and B show 
FCR3CSA and FCR3 infected erythrocytes respectively. In 
these experiments the control serum was a pool of sera 
from malaria naïve Danish volunteers, here shown as a solid 
grey histogram. The IgGmale serum pool is shown as a light-
weight line and the IgGpreg serum pool as a heavyweight line.
The effect of increasing concentrations of trypsin on parasite  adhesion to immobilised CSA and HA Figure 5
The effect of increasing concentrations of trypsin on 
parasite adhesion to immobilised CSA and HA. Para-
site adhesion to 10 µg/ml human umbilical cord HA and 
bovine trachea CSA, adsorbed onto the plastic petri dishes, 
was determined following protease treatment of the intact 
infected erythrocyte. Bound cells were Giemsa stained and 
counted by light microscopy. Panels A and B show receptor 
binding for FCR3 and FCR3CSA infected erythrocytes 
respectively. The bar chart shows mean and standard error 
of the means for three independent experiments.
A. FCR3CSA B. FCR3Malaria Journal 2004, 3:31 http://www.malariajournal.com/content/3/1/31
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Human umbilical cord hyaluronic acid (HA) was also
included in these assays to investigate the binding capac-
ity of the CSA selected clone with respect to this receptor.
FCR3CSA was found to bind both HA and CSA, although
binding to HA was significantly lower (figure 5B; F3,19
20.44, p < 0.001), at 71% that observed for CSA. Interest-
ingly, as has previously been shown for other P. falciparum
isolates [27], the trypsin-sensitivity of parasite adhesion to
HA and CSA differed at low trypsin concentrations (0.01
mg/ml) (figure 5B; F1,8 7.7, p = 0.024). Parasite adhesion
to hyaluronic acid was found to be more sensitive to
trypsinization than adhesion to CSA.
Discussion
The acquisition of antibodies to the surface of placental
isolates correlates with protection from malaria in
pregnancy and the targets of these antibodies are potential
vaccine candidates [13,15]. Two variants of the well char-
acterized VSA, PfEMPl, have been shown to have distinct
CSA-binding domains [29,33] and antibodies raised
against these domains have been reported to recognize
the infected erythrocyte surface [34] and in some cases
block parasite adhesion [35,36]. However, in a recent
study of var gene transcription in CSA-selected clones, a
third potential CSA-binding PfEMPl (var2csa) was identi-
fied. Var2csa is predicted to possess distinctly different
DBL domains and appears to be the major var expressed
by CSA-selected parasites that are recognized by parity-
dependent antibodies [14]. Proteomic analysis of CSA-
selected parasites has also identified four additional
potential CSA binding PfEMPl molecules [37]. The molec-
ular identity of the surface antigens expressed at the
infected erythrocyte surface remains unclear [38]. How-
ever, the differential protease sensitivity of the epitopes
described here would allow treatment of the infected
erythrocyte surface with trypsin thereby simplifying the
surface complexity, thus, potentially making proteomic
approaches more straightforward.
Although PfEMPl-mediated CSA adhesion appears to play
a role in placental malaria the molecular interactions trig-
gering this syndrome are more complex than initially
thought. Several studies implicate additional receptors
and binding phenotypes of placental parasites, such as
non-immune IgM [39], hyaluronic acid [25,27,40] and
non-immune IgG [41]. CSA-binding laboratory clones
and placental CSA binding isolates also appear to express
some parasite encoded surface antigens other than
PfEMPl, such as ring surface proteins 1 and 2 (RSP 1 and
2) [42]. Interestingly, a gene 'knock-out' of the CSA bind-
ing var (FCR3varCSA) in parasite clone FCR3 abolishes
CSA binding, but the 'knock-out' parasites still bind the
syncytio-trophoblast of ex vivo placental cryosections [43].
Monoclonal antibodies raised against the CSA binding
DBLγ domain also show this domain to be sensitive to
surface proteolysis using relatively low trypsin concentra-
tions (100 µg/ml) [34]. It is certainly possible that the
trypsin-resistant VSA described here are not of the
PfEMPl/CSA binding type.
Surface epitopes of the FCR3CSA parasite are both highly
resistant to trypsin and are recognized by antibodies from
malaria-exposed pregnant women. This agrees with a
number of studies that have found parasite adhesion to
placental receptors to be resistant to surprisingly high
trypsin concentrations. However, binding assays with the
parasite clone used in this study showed CSA and HA
adhesion to be relatively trypsin-sensitive. This is also
compatible with the results of Beeson and his colleagues
who demonstrated trypsin-resistant CSA adhesion to be a
clone dependent phenomenon [27]. Another recent study
by the same group showed sera that is strongly reactive to
the surface of CSA selected parasites is not always capable
of inhibiting CSA adhesion [44]. Thus this study supports
the view that erythrocyte surface epitopes distinct from
those involved in CSA adhesion may be targets of the anti-
bodies acquired during PAM and suggests that these two
epitopes could be on different molecules. One further
implication for vaccine development is that a candidate
vaccine raising only CSA adhesion blocking antibodies
may not mimic protective surface reactive gender-specific
immune responses.
Conclusion
This study supports the view that major differences exist
between VSAPAM and previously characterized VSA. Apart
from being recognized only by female sera in a parity-
dependent manner, VSAPAM show other distinct character-
istics such as; i) VSAPAM rarely form infected erythrocyte
rosettes when compared to CD36 binding VSA [27,45], ii)
with the exception of rosetting isolates, non-immune IgM
binding is a phenomenon only seen with CSA-binding
clones [39], iii) VSAPAM do not generally mediate adhe-
sion to CD36 [27,46], and iv) VSAPAM mediated adhesion
to the placenta and CSA can be resistant to concentrations
of trypsin known to remove most PfEMPl molecules from
the infected cell surface. In combination with the findings
of this study, these distinct properties of VSAPAM suggest
the involvement of either an unusually protease-resistant
PfEMPl structure, such has been shown to exist in the
A4tres PfEMPl molecule [47] or an alternative class of VSA
in placental adhesion. The differential protease sensitivity
exhibited by VSAPAM can be exploited in comparative pro-
teomic analysis to aid in the identification of the mole-
cules whose phenotype is described here.
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